Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

INTRODUCTION: The osimertinib (AZD9291) US Expanded Access Program (EAP) provided compassionate access to osimertinib prior to US Food and Drug Administration (FDA) approval for patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Edgardo S., Kaplan, Barry, Kirshner, Eli, Croft, Elisabeth F., Sequist, Lecia V., Chau, MyDoanh, Munley, Jiefen, Oxnard, Geoffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359991/
https://www.ncbi.nlm.nih.gov/pubmed/32700141
http://dx.doi.org/10.1007/s40487-018-0061-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359991/
https://www.ncbi.nlm.nih.gov/pubmed/32700141
http://dx.doi.org/10.1007/s40487-018-0061-y

Ejemplares similares